[ 177 Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].

BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and 223 Ra), most of these patients still succumb to prostate cancer. Recently, 177 lutetium prostate-specific membrane antigen radioligand therapy (177 Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy.

OBJECTIVES: Establishment of the current position of 177 Lu-PSMA-RLT in mCRPC in 2017.

MATERIALS AND METHODS: Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on 177 Lu-PSMA-RLT after PubMed-based research.

RESULTS: In several larger retrospective studies, 177 Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile.

CONCLUSIONS: Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with 177 Lu-PSMA-RLT in the treatment of mCRPC.